Details of Disease

General Information of Disease (ID: DISEWP9B)

• Disease Name: Multiple myeloma
• Disease Class: 2A83: Multiple myeloma
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISEWP9B: Multiple myeloma
• ICD Code:
  ICD-11: ICD-11: 2A83
  ICD-10: ICD-10: C90
• Disease Identifiers:
  MONDO ID: MONDO_0005374
  MESH ID: D019046
  UMLS CUI: C0282609
  OMIM ID: 254500
  MedGen ID: 129203
  HPO ID: HP:0006775
  Orphanet ID: 29073
  SNOMED CT ID: 414824005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 29 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[1]
Belantamab mafodotin	DMBT3AI	Approved	Antibody drug conjugate	[2]
Bortezomib	DMNO38U	Approved	Small molecular drug	[3]
Carfilzomib	DM48K0X	Approved	Small molecular drug	[4]
Cerivastatin	DMXCM7H	Approved	Small molecular drug	[5]
Daratumumab	DMKCIUZ	Approved	Antibody	[6]
Dasatinib	DMJV2EK	Approved	Small molecular drug	[7]
Dostarlimab	DM78NWP	Approved	Antibody	[8]
Elotuzumab	DMEYHG9	Approved	Antibody	[9]
Elranatamab	DMG1MW2	Approved	Antibody	[10]
Futibatinib	DMWM4D0	Approved	NA	[11]
Idecabtagene vicleucel	DMP1QTS	Approved	CAR T Cell Therapy	[12]
Isatuximab	DMF7HVU	Approved	NA	[13]
Ixazomib	DM5ZVLB	Approved	NA	[14]
Lenalidomide	DM6Q7U4	Approved	Small molecular drug	[15]
Melphalan	DMOLNHF	Approved	Small molecular drug	[16]
Melphalan flufenamide	DMWF5R4	Approved	Small molecular drug	[17]
Metadoxine	DMM4QOJ	Approved	Small molecular drug	[18]
MLN9708	DMCMETN	Approved	Small molecular drug	[19]
Motixafortide	DMW34B1	Approved	Peptide	[20]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[1]
Panobinostat	DM58WKG	Approved	Small molecular drug	[21]
Romiplostim	DM3U7SZ	Approved	Small molecular drug	[22]
Siltuximab	DMGEATB	Approved	Antibody	[1]
Sirolimus	DMGW1ID	Approved	Small molecular drug	[23]
Talquetamab	DMXRENI	Approved	Monoclonal antibody	[24]
Teclistamab	DMGR8JI	Approved	NA	[25]
Thalidomide	DM70BU5	Approved	Small molecular drug	[26]
Trapidil	DMY67U8	Phase 4	Small molecular drug	[5]

This Disease is Treated as An Indication in 196 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABC294640	DMCKPG4	Phase 3	Small molecular drug	[1]
Ciltacabtagene autoleucel	DMU2J7Y	Phase 3	CAR T Cell Therapy	[27]
Galinpepimut-S	DMTEQEQ	Phase 3	NA	[1]
GMI-1271	DMDTGWQ	Phase 3	?	[1]
Marizomib	DME9QGW	Phase 3	Small molecular drug	[28]
NVP-LAQ824	DM8JWNA	Phase 3	Small molecular drug	[5]
Oblimersen	DM7KI4E	Phase 3	NA	[29]
Pelareorep	DM4WCF9	Phase 3	NA	[30]
Plitidepsin	DMJ8AUE	Phase 3	Small molecular drug	[28]
Selinexor	DMBD4K3	Phase 3	Small molecular drug	[23]
T89	DMC7E5X	Phase 3	Small molecular drug	[31]
Tabalumab	DMKSAG1	Phase 3	Monoclonal antibody	[32]
Ulocuplumab	DM6PMNR	Phase 3	Monoclonal antibody	[33]
Imetelstat	DMONWJ4	Phase 2/3	Small molecular drug	[34]
ALT-803	DMK3U1X	Phase 2	NA	[1]
ARRY-520	DMTOI7S	Phase 2	Small molecular drug	[28]
Bb2121	DMB0UF9	Phase 2	CAR T Cell Therapy	[1]
BHQ880	DMSROM4	Phase 2	Antibody	[35]
BI-505	DMSZQHX	Phase 2	Antibody	[28]
BT-062	DMYO185	Phase 2	Antibody	[1]
Captisol-enabled Melphalan	DMI7VQU	Phase 2	NA	[36]
CAR-T cells targeting CD22	DM6XN4C	Phase 2	CAR T Cell Therapy	[37]
CAR-T cells targeting CD30	DML0KWM	Phase 2	CAR T Cell Therapy	[37]
CART-19 cells	DMZUV7T	Phase 2	CAR T Cell Therapy	[38]
CC-220	DMNE7L3	Phase 2	Small molecular drug	[1]
CDX-301	DMKRFCO	Phase 2	NA	[1]
CJM112	DMTSVJM	Phase 2	NA	[1]
CLR 131	DM6135B	Phase 2	Small molecular drug	[28]
CLR-131	DMDM2DF	Phase 2	NA	[1]
Darinaparsin	DMB4OFL	Phase 2	Small molecular drug	[39]
Delanzomib	DMX4DQH	Phase 2	Small molecular drug	[40]
Descartes-08	DM63P1W	Phase 2	CAR T Cell Therapy	[41]
Descartes-11	DM1UO4S	Phase 2	CAR T Cell Therapy	[42]
DKN-01	DMOHT5V	Phase 2	Antibody	[43]
Ficlatuzumab	DMG65WH	Phase 2	Monoclonal antibody	[44]
GL-0817	DM17OZM	Phase 2	Small molecular drug	[45]
GSK2110183	DMZHB37	Phase 2	Small molecular drug	[46]
GSK2857916	DM57BH8	Phase 2	NA	[1]
GSK3377794	DMQ4RWW	Phase 2	NA	[1]
GVAX	DMW8YZ9	Phase 2	NA	[47]
INCB00928	DMFG8TI	Phase 2	Small molecular drug	[48]
Indatuximab ravtansine	DMG7YNI	Phase 2	Monoclonal antibody	[30]
INK128	DMGO7QT	Phase 2	Small molecular drug	[49]
IPH-2101	DMDUVCZ	Phase 2	NA	[50]
JNJ 63723283	DMBXWJ5	Phase 2	Monoclonal antibody	[1]
LCAR-B38M CAR-T Cell	DMQZJNA	Phase 2	CAR T Cell Therapy	[51]
LCL161	DMTM4QA	Phase 2	NA	[1]
mab 1-7F9	DMQOBH4	Phase 2	Antibody	[52]
Myeloma cancer vaccine	DMO1XUK	Phase 2	Vaccine	[53]
NVP-AUY922	DMTYXQF	Phase 2	Small molecular drug	[54]
ONC201	DMM5SCF	Phase 2	NA	[1]
Oprozomib	DM16RIC	Phase 2	Small molecular drug	[1]
PVX-410	DM6DK9A	Phase 2	NA	[55]
RAPA-201	DMUKXX5	Phase 2	Cell therapy	[56]
Rocilinostat	DMSTH01	Phase 2	Small molecular drug	[57]
SurVaxM	DMAIGTE	Phase 2	NA	[55]
Tanespimycin	DMNLQHK	Phase 2	Small molecular drug	[58]
Ygalo	DMM397E	Phase 2	NA	[1]
Anti-BCMA CAR-T cells	DM4D3YF	Phase 1/2	CAR T Cell Therapy	[59]
Anti-BCMA-CAR-transduced T cells	DMZ18IO	Phase 1/2	CAR T Cell Therapy	[60]
Anti-CD38 CAR-T cells	DMTVXBY	Phase 1/2	CAR T Cell Therapy	[59]
Anti-NY-ESO-1 CAR-T cells	DM26VCZ	Phase 1/2	CAR T Cell Therapy	[59]
AR-42	DML44FR	Phase 1/2	Small molecular drug	[61]
Atiprimod	DM84YEC	Phase 1/2	Small molecular drug	[5]
AUTO2	DM0PWX2	Phase 1/2	CAR T Cell Therapy	[62]
BCMA CAR T cells	DMH70A9	Phase 1/2	CAR T Cell Therapy	[63]
BCMA CAR-T	DM1DHPO	Phase 1/2	CAR T Cell Therapy	[64]
BION-1301	DMCDNEC	Phase 1/2	NA	[1]
BIW-8962	DMZEA9X	Phase 1/2	Antibody	[65]
CAR-T cells targeting BCMA	DMENIQ7	Phase 1/2	CAR T Cell Therapy	[37]
CAR-T cells targeting CD19	DMIM9TZ	Phase 1/2	CAR T Cell Therapy	[37]
CAR-T cells targeting CLL1	DMCPM92	Phase 1/2	CAR T Cell Therapy	[37]
CART-138 cells	DMB4HEW	Phase 1/2	CAR T Cell Therapy	[66]
CART-19/BCMA	DMVW1GY	Phase 1/2	CAR T Cell Therapy	[67]
CART-BCMA cells	DMWOYNT	Phase 1/2	CAR T Cell Therapy	[66]
CC-92480	DMEW6PD	Phase 1/2	NA	[68]
CD138 CAR T cells	DMCSGNU	Phase 1/2	CAR T Cell Therapy	[63]
CD38 and BCMA CAR-T Cells	DMFZS8A	Phase 1/2	CAR T Cell Therapy	[69]
CD38 CAR T cells	DMPS3I6	Phase 1/2	CAR T Cell Therapy	[63]
CD56 CAR T cells	DMS5OL0	Phase 1/2	CAR T Cell Therapy	[63]
CWP232291	DMBUYIK	Phase 1/2	Small molecular drug	[1]
ImMucin	DM09JOZ	Phase 1/2	Vaccine	[70]
ISB 1342	DMG107N	Phase 1/2	Antibody	[71]
JCAR017	DMJV2IF	Phase 1/2	CAR T Cell Therapy	[72]
JCARH125	DM8P7FC	Phase 1/2	CAR T Cell Therapy	[72]
JNJ-68284528	DMD9X6U	Phase 1/2	CAR T Cell Therapy	[73]
LGH-447	DMQN9ME	Phase 1/2	NA	[74]
Milatuzumab-doxorubicin conjugate	DMWQ38D	Phase 1/2	Antibody drug conjugate	[75]
Modakafusp alfa	DMB5N7B	Phase 1/2	NA	[76]
MOR-202	DMR8AHJ	Phase 1/2	Antibody	[77]
NEXI-002	DM1RAIS	Phase 1/2	Cell therapy	[78]
NY-ESO-TCR	DMS0L6J	Phase 1/2	NA	[30]
P-BCMA-101	DMB4SSZ	Phase 1/2	CAR T Cell Therapy	[79]
PBCAR269A	DMSGM2L	Phase 1/2	CAR T Cell Therapy	[80]
REGN5458	DMAGX0Q	Phase 1/2	Antibody	[81]
REGN5459	DMRE0LU	Phase 1/2	Antibody	[82]
SL-401	DMOCHVE	Phase 1/2	NA	[1]
Tinostamustine	DMA4DMQ	Phase 1/2	Small molecule	[83]
131I-labelled CLR1404	DMI3UD6	Phase 1	Radiopharmaceutical therapy agent	[84]
225Ac-labelled aCD38	DM3E2IY	Phase 1	Radiopharmaceutical therapy agent	[85]
ABBV-467	DM87SM9	Phase 1	Small molecular drug	[86]
ABBV-838	DMZM0T8	Phase 1	NA	[30]
Actimab-M	DM5KMYQ	Phase 1	NA	[30]
ACTR-BCMA	DM6ORVM	Phase 1	NA	[1]
AEW-541	DMQF982	Phase 1	Small molecular drug	[87]
ALLO-715	DMHE3MD	Phase 1	CAR T Cell Therapy	[88]
AMG 176	DM0Q7NO	Phase 1	NA	[1]
AMG 224	DMPG567	Phase 1	NA	[1]
AMG 420	DMYFZLA	Phase 1	Antibody	[1]
AMG 424	DMLAP8F	Phase 1	Antibody	[89]
AMG 701	DM6IT3M	Phase 1	Antibody	[1]
Anti-BCMA CAR T cells	DM3OFZC	Phase 1	CAR T Cell Therapy	[90]
Anti-BCMA CAR-T cell therapy	DMB4G3E	Phase 1	NA	[30]
Anti-BCMA CAR-T cells	DM2TFUD	Phase 1	CAR T Cell Therapy	[91]
Anti-BCMA CART Cells	DMUKNDO	Phase 1	CAR T Cell Therapy	[92]
Anti-CD19 CART Cells	DMW549Y	Phase 1	CAR T Cell Therapy	[92]
Anti-CD19/BCMA CAR-T cells	DMF93T2	Phase 1	CAR T Cell Therapy	[93]
Anti-CD38 CAR-T cell therapy	DMAJH1B	Phase 1	NA	[1]
Anti-FGFR3	DM6QENU	Phase 1	Antibody	[94]
APO-010	DMPJBCR	Phase 1	NA	[95]
ATA520	DMM2VFS	Phase 1	NA	[30]
BB-MPI-03	DM0PII2	Phase 1	NA	[55]
Bb21217	DMSBWAQ	Phase 1	CAR T Cell Therapy	[96]
BCMA CAR-T Cells	DMJ4W5V	Phase 1	CAR T Cell Therapy	[97]
BCMA CART	DMJ37LH	Phase 1	CAR T Cell Therapy	[98]
BCMA CART and huCART19	DM2V4EO	Phase 1	CAR T Cell Therapy	[98]
BCMA nanobody CAR-T cells	DMZDLHV	Phase 1	CAR T Cell Therapy	[99]
BCMA-CD19 cCAR	DMZ13WQ	Phase 1	CAR T Cell Therapy	[100]
BCMA-CS1 cCAR	DMEPHMR	Phase 1	CAR T Cell Therapy	[101]
BFCR4350A	DMEJ2C8	Phase 1	NA	[1]
C-CAR088	DMT35N2	Phase 1	CAR T Cell Therapy	[102]
CAR-T cells targeting BCMA	DMTZADW	Phase 1	CAR T Cell Therapy	[103]
CAR138 T Cells	DMA9M81	Phase 1	CAR T Cell Therapy	[104]
CART-19 T cells	DMTCB8I	Phase 1	CAR T Cell Therapy	[105]
CART-BCMA	DMVK3M2	Phase 1	CAR T Cell Therapy	[106]
CART-ddBCMA	DM4OWJ8	Phase 1	CAR T Cell Therapy	[107]
CB-5083	DM12GN7	Phase 1	NA	[108]
CC-115	DMYEB5F	Phase 1	Small molecular drug	[109]
CC-122	DM0SRAN	Phase 1	Small molecular drug	[1]
CC-93269	DM1M4B8	Phase 1	Antibody	[1]
CC-98633	DM69YM1	Phase 1	CAR T Cell Therapy	[110]
CC-99712	DM1UEBR	Phase 1	Antibody drug conjugate	[111]
CD38 CAR-T	DMNX0V7	Phase 1	CAR T Cell Therapy	[112]
Citarinostat	DMQLODU	Phase 1	NA	[1]
CM-CS1 T-cell	DMY5V4U	Phase 1	CAR T Cell Therapy	[113]
CT053	DMBCJW6	Phase 1	CAR T Cell Therapy	[114]
CTX120	DMWS40H	Phase 1	CAR T Cell Therapy	[115]
DFRF4539A	DM1QV2G	Phase 1	NA	[116]
FOR46	DMKX174	Phase 1	Antibody drug conjugate	[117]
FT538	DMV20B8	Phase 1	Cell therapy	[118]
GBR 1342	DMN35Z0	Phase 1	NA	[1]
GPRC5D CAR-T cell therapy	DM8MGSH	Phase 1	CAR T Cell Therapy	[119]
GRN163	DMGF71W	Phase 1	Small molecular drug	[5]
HPN217	DMI0KQW	Phase 1	NA	[120]
IM21 CART	DMTNYIB	Phase 1	CAR T Cell Therapy	[121]
JNJ-64407564	DMPN2IL	Phase 1	NA	[1]
JNJ-79635322	DMSEGKC	Phase 1	NA	[122]
KITE-585	DMXR6HI	Phase 1	CAR T Cell Therapy	[1]
KP1237	DMCGY7Q	Phase 1	Antibody	[123]
LCAR-B4822M CAR-T Cell	DMEY2LK	Phase 1	CAR T Cell Therapy	[124]
M3258	DM6PI5B	Phase 1	Small molecular drug	[125]
MB-104	DMRP4BM	Phase 1	CAR T Cell Therapy	[126]
MEDI2228	DMX0DUH	Phase 1	Antibody drug conjugate	[127]
Mivebresib	DMCPF90	Phase 1	NA	[1]
MTV273	DMYPNQA	Phase 1	NA	[1]
NAM-NK cells	DMTWKVH	Phase 1	Cell therapy	[128]
NAM-NK cells + IL-2	DMEXQNL	Phase 1	NA	[1]
Natural killer cell therapy	DM9M9GJ	Phase 1	NA	[129]
P-BCMA-101 CAR-T cells	DMDC9TB	Phase 1	CAR T Cell Therapy	[79]
PF-06688992	DM2VCI3	Phase 1	NA	[30]
PF-06863135	DMKI95J	Phase 1	NA	[1]
PHE885	DMBZ2QT	Phase 1	CAR T Cell Therapy	[130]
PNK-007	DMI344Y	Phase 1	NA	[1]
PT-112	DMB6M1P	Phase 1	Small molecular drug	[1]
RG6234	DMYUSOJ	Phase 1	Bispecific antibody	[131]
RG6296	DMEFUSJ	Phase 1	Antibody	[132]
RG6538	DMTRKEB	Phase 1	CAR-T cell therapy	[131]
RO6870810	DM7H6XI	Phase 1	Small molecular drug	[133]
SEA-BCMA	DM7NP1K	Phase 1	Antibody	[134]
SGN-CD352A	DM0O2EU	Phase 1	NA	[1]
SGN-CD48A	DMFPVA0	Phase 1	NA	[1]
STRO-001	DMOPQRE	Phase 1	NA	[1]
TAK-169	DMRINBJ	Phase 1	Recombinant protein	[135]
TAK-573	DMUXAP1	Phase 1	Recombinant protein	[136]
TNB-383B	DMAI0SH	Phase 1	Antibody	[137]
UCARTCS1	DM2Y4D7	Phase 1	CAR T Cell Therapy	[138]
VLX1570	DMYQ0DV	Phase 1	NA	[28]
VOB560	DMDG30Q	Phase 1	Small molecular drug	[139]
WVT078	DM7MS10	Phase 1	Antibody	[140]
BCMA-CART	DMCEPKM	Clinical trial	CAR T Cell Therapy	[141]
BCMA-UCART	DMWXGRQ	Clinical trial	CAR T Cell Therapy	[142]
CAR-BCMA T cell	DMLF2UY	Clinical trial	CAR T Cell Therapy	[143]
CAR-T cells targeting BCMA	DMGW10M	Clinical trial	CAR T Cell Therapy	[144]
CAR-T cells targeting CD138	DMHBQYU	Clinical trial	CAR T Cell Therapy	[144]
CAR-T cells targeting CD38	DMH5C37	Clinical trial	CAR T Cell Therapy	[144]
CAR-T cells targeting CD56	DMAK1ME	Clinical trial	CAR T Cell Therapy	[144]

This Disease is Treated as An Indication in 4 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AS602868	DMKXDOI	Discontinued in Phase 1	Small molecular drug	[145]
RG7598	DMKIU7O	Discontinued in Phase 1	NA	[146]
AG490	DM3WKO5	Terminated	Small molecular drug	[150]
zoxazolamine	DM70TKB	Terminated	Small molecular drug	[151]

This Disease is Treated as An Indication in 3 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
211At-labelled aLAT-1	DME2RZW	Preclinical	Radiopharmaceutical therapy agent	[147]
P-BCMA-ALL01	DMNIM96	Preclinical	CAR T Cell Therapy	[148]
UCART-CLL1	DMT06MI	Preclinical	CAR T Cell Therapy	[149]

This Disease is Treated as An Indication in 19 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AbGn-150	DMVHAQY	Investigative	NA	[152]
ACHP	DMZO5Y7	Investigative	Small molecular drug	[5]
Anti-HM1.24	DM2GLD6	Investigative	NA	[152]
BAY11-7082	DMQNOFA	Investigative	Small molecular drug	[153]
BIBF100	DMUWO6D	Investigative	NA	[5]
CCX-721	DMDUP9Q	Investigative	NA	[152]
CGEN-928	DMKB4FX	Investigative	NA	[152]
FM-101	DMXK6EI	Investigative	NA	[154]
GNE-652	DM736OU	Investigative	NA	[152]
JB-1	DM38L1B	Investigative	Small molecular drug	[5]
NVP-ADW742	DMXL3CD	Investigative	Small molecular drug	[5]
PS-1145	DMVUMWZ	Investigative	Small molecular drug	[5]
Sant7	DM9CV4P	Investigative	Small molecular drug	[5]
SU5402	DM9JON3	Investigative	Small molecular drug	[5]
Telomestatin	DM6EIVM	Investigative	Small molecular drug	[5]
TMPyP4	DMWO85H	Investigative	Small molecular drug	[5]
TP-110	DMMX5DA	Investigative	Small molecular drug	[152]
Tubacin	DMYR8SG	Investigative	Small molecular drug	[155]
UCL-67022	DMFYUMX	Investigative	NA	[156]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7420).
• [5] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7395).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678).
• [8] ClinicalTrials.gov (NCT04126200) Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). U.S. National Institutes of Health.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8361).
• [10] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [11] ClinicalTrials.gov (NCT02052778) A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities. U.S. National Institutes of Health.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7620).
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [18] ClinicalTrials.gov (NCT02051842) Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis. U.S. National Institutes of Health.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8450).
• [20] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217159
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056).
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [24] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [25] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7327).
• [27] ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
• [28] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8269).
• [30] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [31] ClinicalTrials.gov (NCT01659580) Phase III Trial of Dantonic (T89) Capsule to Prevent and Treat Stable Angina. U.S. National Institutes of Health.
• [32] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8000).
• [33] Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661.
• [34] ClinicalTrials.gov (NCT02426086) Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. U.S. National Institutes of Health.
• [35] ClinicalTrials.gov (NCT01302886) Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma. U.S. National Institutes of Health.
• [36] Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled (Propylene Glycol-Free) Melphalan. Spectrum Pharmaceuticals. October 23, 2015.
• [37] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [38] ClinicalTrials.gov (NCT02794246) CART-19 Post-ASCT for Multiple Myeloma
• [39] ClinicalTrials.gov (NCT00421213) Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers. U.S. National Institutes of Health.
• [40] Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Curr Cancer Drug Targets. 2014;14(6):517-36.
• [41] ClinicalTrials.gov (NCT04816526) Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health.
• [42] ClinicalTrials.gov (NCT04436029) Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health.
• [43] ClinicalTrials.gov (NCT01711671) A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [44] ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health.
• [45] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035081)
• [46] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7890).
• [47] Clinical pipeline report, company report or official report of Aduro.
• [48] ClinicalTrials.gov (NCT04582539) To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.. U.S. National Institutes of Health.
• [49] ClinicalTrials.gov (NCT02244463) A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
• [50] ClinicalTrials.gov (NCT01222286) Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma. U.S. National Institutes of Health.
• [51] ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
• [52] Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
• [53] ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
• [54] ClinicalTrials.gov (NCT01854034) Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR. U.S. National Institutes of Health.
• [55] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [56] ClinicalTrials.gov (NCT04176380) RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [57] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032606)
• [58] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7751).
• [59] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [60] ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
• [61] Clinical pipeline report, company report or official report of Arno Therapeutics.
• [62] ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
• [63] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [64] ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma
• [65] ClinicalTrials.gov (NCT01898156) Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer. U.S. National Institutes of Health.
• [66] ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
• [67] ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
• [68] ClinicalTrials.gov (NCT03374085) A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM). U.S. National Institutes of Health.
• [69] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [70] ClinicalTrials.gov (NCT01232712) A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies. U.S. National Institutes of Health.
• [71] ClinicalTrials.gov (NCT03309111) Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
• [73] ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
• [74] ClinicalTrials.gov (NCT02144038) Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [75] ClinicalTrials.gov (NCT01101594) A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma. U.S. National Institutes of Health.
• [76] ClinicalTrials.gov (NCT05590377) A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.
• [77] ClinicalTrials.gov (NCT01421186) A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [78] ClinicalTrials.gov (NCT04505813) Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [79] ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
• [80] ClinicalTrials.gov (NCT04171843) A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [81] ClinicalTrials.gov (NCT03761108) First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [82] ClinicalTrials.gov (NCT04083534) First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM). U.S. National Institutes of Health.
• [83] ClinicalTrials.gov (NCT03687125) Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1). U.S.National Institutes of Health.
• [84] ClinicalTrials.gov (NCT02278315) Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [85] ClinicalTrials.gov (NCT02998047) A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [86] ClinicalTrials.gov (NCT04178902) A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma. U.S. National Institutes of Health.
• [87] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019974)
• [88] ClinicalTrials.gov (NCT04093596) Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL). U.S. National Institutes of Health.
• [89] ClinicalTrials.gov (NCT03445663) Study Evaluating AMG 424 in Subjects With Multiple Myeloma. U.S. National Institutes of Health.
• [90] ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma
• [91] ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
• [92] ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
• [93] ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
• [94] Clinical pipeline report, company report or official report of Genentech (2011).
• [95] APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64.
• [96] ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma
• [97] ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
• [98] ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
• [99] ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
• [100] ClinicalTrials.gov (NCT04162353) BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma. U.S. National Institutes of Health.
• [101] ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [102] ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
• [103] ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
• [104] ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
• [105] ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma
• [106] ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma
• [107] Clinical pipeline report, company report or official report of Arcellx.
• [108] ClinicalTrials.gov (NCT02243917) A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [109] ClinicalTrials.gov (NCT01353625) Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.. U.S. National Institutes of Health.
• [110] ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [111] ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [112] Clinical pipeline report, company report or official report of Sorrento Therapeutics.
• [113] ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
• [114] ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health.
• [115] ClinicalTrials.gov (NCT04244656) A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [116] ClinicalTrials.gov (NCT01432353) A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [117] ClinicalTrials.gov (NCT03650491) A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM). U.S. National Institutes of Health.
• [118] ClinicalTrials.gov (NCT04614636) FT538 in Subjects With Advanced Hematologic Malignancies. U.S. National Institutes of Health.
• [119] Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
• [120] ClinicalTrials.gov (NCT04184050) A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM. U.S. National Institutes of Health.
• [121] ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
• [122] ClinicalTrials.gov (NCT05652335) Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis. U.S.National Institutes of Health.
• [123] ClinicalTrials.gov (NCT04634435) A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Formerly KP1237) and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission. U.S.National Institutes of Health.
• [124] ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
• [125] ClinicalTrials.gov (NCT04075721) First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone. U.S. National Institutes of Health.
• [126] ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma. U.S. National Institutes of Health.
• [127] ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health.
• [128] ClinicalTrials.gov (NCT03019666) Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL. U.S. National Institutes of Health.
• [129] Clinical pipeline report, company report or official report of Karolinska Institute.
• [130] ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [131] Clinical pipeline report, company report or official report of Roche
• [132] ClinicalTrials.gov (NCT04434469) A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [133] ClinicalTrials.gov (NCT03068351) Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma. U.S. National Institutes of Health.
• [134] ClinicalTrials.gov (NCT03582033) A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.
• [135] ClinicalTrials.gov (NCT04017130) A Study of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [136] ClinicalTrials.gov (NCT03215030) A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM). U.S. National Institutes of Health.
• [137] ClinicalTrials.gov (NCT03933735) A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [138] ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.
• [139] ClinicalTrials.gov (NCT04702425) VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma). U.S. National Institutes of Health.
• [140] ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.
• [141] ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
• [142] ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART
• [143] ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• [144] ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
• [145] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009941)
• [146] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035041)
• [147] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [148] Clinical pipeline report, company report or official report of Poseida Therapeutics.
• [149] Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
• [150] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5916).
• [151] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2327).
• [152] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [153] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5934).
• [154] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
• [155] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7374).
• [156] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618).
• [157] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.